Erasca, Inc.
ERAS
Classement en actions
#3371
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Prix de l'action
$14.51
Dernière synchronisation: 2026-10-21
Capitalisation boursière
$5.08B
Changement (1 jour)
-0.75%
Changement (1 an)
539.21%
Pays
US
Échange Erasca, Inc. (ERAS)
Catégorie
Healthcare
Historique du prix de l'action pour Erasca, Inc. (ERAS)
Prix de clôture le plus élevé : $14.66 le 2026-10-01
Prix de clôture le plus bas : $19.40 le 2021-07-01
Prix de clôture le plus bas : $19.40 le 2021-07-01
Historique du prix de l'action de Erasca, Inc. de 2021 à 2026
Performance annuelle du prix de l'action
| Année | Performance |
|---|---|
| 2026 (TTM) | 260.18% |
| 2025 | 24.72% |
| 2024 | 41.38% |
| 2023 | -63.49% |
| 2022 | -62.73% |
| 2021 | 0.00% |
Prix de l'action pour des entreprises similaires ou concurrentes
| Entreprise | Prix de l'action | Variation 1a% | Pays |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $765.49 | 8.80% |
CH
|
